327 related articles for article (PubMed ID: 30191649)
1. Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience.
Pareek N; Cevallos J; Moliner P; Shah M; Tan LL; Chambers V; Baksi AJ; Khattar RS; Sharma R; Rosen SD; Lyon AR
Eur J Heart Fail; 2018 Dec; 20(12):1721-1731. PubMed ID: 30191649
[TBL] [Abstract][Full Text] [Related]
2. Brazilian cardio-oncology: the 10-year experience of the Instituto do Cancer do Estado de Sao Paulo.
Costa IBSDS; Bittar CS; Fonseca SMR; E Silva CMPD; Dos Santos Rehder MHH; Rizk SI; Cruz CBBV; Figueiredo CS; de A Andrade FT; Barberino LA; de S Costa FA; Machado LP; González TB; Almeida MPC; Fukushima JT; Kalil Filho R; Hajjar LA
BMC Cardiovasc Disord; 2020 Apr; 20(1):206. PubMed ID: 32345217
[TBL] [Abstract][Full Text] [Related]
3. Development of a Cardio-Oncology Service in Lithuania: Prediction, Prevention, Monitoring and Treatment of Cancer Treatment-Induced Cardiotoxicity.
Čiburienė E; Aidietienė S; Ščerbickaitė G; Brasiūnienė B; Drobnienė M; Baltruškevičienė E; Žvirblis T; Čelutkienė J
J Cardiovasc Dev Dis; 2022 Apr; 9(5):. PubMed ID: 35621845
[TBL] [Abstract][Full Text] [Related]
4. Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology.
Kostakou PM; Kouris NT; Kostopoulos VS; Damaskos DS; Olympios CD
Heart Fail Rev; 2019 Jan; 24(1):91-100. PubMed ID: 30073443
[TBL] [Abstract][Full Text] [Related]
5. Optimizing cardio-oncology programs for cancer patients.
Francis SA; Asnani A; Neilan T; Scherrer-Crosbie M
Future Oncol; 2015; 11(14):2011-5. PubMed ID: 26198828
[No Abstract] [Full Text] [Related]
6. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease.
Totzeck M; Schuler M; Stuschke M; Heusch G; Rassaf T
Int J Cardiol; 2019 Apr; 280():163-175. PubMed ID: 30661849
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular management of cancer patients with chemotherapy-associated left ventricular systolic dysfunction in real-world clinical practice.
Ammon M; Arenja N; Leibundgut G; Buechel RR; Kuster GM; Kaufmann BA; Pfister O
J Card Fail; 2013 Sep; 19(9):629-34. PubMed ID: 24054339
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms.
Linde C; Abraham WT; Gold MR; St John Sutton M; Ghio S; Daubert C;
J Am Coll Cardiol; 2008 Dec; 52(23):1834-1843. PubMed ID: 19038680
[TBL] [Abstract][Full Text] [Related]
9. Cardio-Oncology at the Beginning of a New Decade.
Grumbach IM
J Am Heart Assoc; 2020 Jan; 9(2):e015890. PubMed ID: 31959029
[No Abstract] [Full Text] [Related]
10. Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity.
Wickramasinghe CD; Nguyen KL; Watson KE; Vorobiof G; Yang EH
Future Oncol; 2016 Mar; 12(6):855-70. PubMed ID: 26829050
[TBL] [Abstract][Full Text] [Related]
11. Cardio-Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction.
Tromp J; Steggink LC; Van Veldhuisen DJ; Gietema JA; van der Meer P
Clin Pharmacol Ther; 2017 Apr; 101(4):481-490. PubMed ID: 28073142
[No Abstract] [Full Text] [Related]
12. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.
Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M
Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821
[TBL] [Abstract][Full Text] [Related]
13. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
14. Cardio-oncology: cardiovascular complications of cancer therapy.
Henning RJ; Harbison RD
Future Cardiol; 2017 Jul; 13(4):379-396. PubMed ID: 28660778
[TBL] [Abstract][Full Text] [Related]
15. Practices in management of cancer treatment-related cardiovascular toxicity: A cardio-oncology survey.
Jovenaux L; Cautela J; Resseguier N; Pibarot M; Taouqi M; Orabona M; Pinto J; Peyrol M; Barraud J; Laine M; Bonello L; Paganelli F; Barlesi F; Thuny F
Int J Cardiol; 2017 Aug; 241():387-392. PubMed ID: 28365180
[TBL] [Abstract][Full Text] [Related]
16. Cardio-oncology: role of echocardiography.
Villarraga HR; Herrmann J; Nkomo VT
Prog Cardiovasc Dis; 2014; 57(1):10-8. PubMed ID: 25081398
[TBL] [Abstract][Full Text] [Related]
17. Introduction to the Cardio-Oncology Miniseries.
Davidoff R; Fifer M; Francis S
Circulation; 2015 Nov; 132(19):1834. PubMed ID: 26553712
[No Abstract] [Full Text] [Related]
18. Cardio-oncology: an ongoing evolution.
Petek BJ; Greenman C; Herrmann J; Ewer MS; Jones RL
Future Oncol; 2015; 11(14):2059-66. PubMed ID: 26198836
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.
Chioncel O; Lainscak M; Seferovic PM; Anker SD; Crespo-Leiro MG; Harjola VP; Parissis J; Laroche C; Piepoli MF; Fonseca C; Mebazaa A; Lund L; Ambrosio GA; Coats AJ; Ferrari R; Ruschitzka F; Maggioni AP; Filippatos G
Eur J Heart Fail; 2017 Dec; 19(12):1574-1585. PubMed ID: 28386917
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN).
Pituskin E; Haykowsky M; McNeely M; Mackey J; Chua N; Paterson I
BMC Cancer; 2016 Sep; 16(1):733. PubMed ID: 27629548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
